Why did the FDA change course on Moderna’s flu shot?

From refusal to review to a renewed regulatory review

Regulators initially declined to consider Moderna’s application for an mRNA influenza vaccine, but the agency later reversed that decision and agreed to accept the company’s submission for formal review. Moderna said the change followed further discussions with the Food and Drug Administration and that the agency will now evaluate the data the company has provided.

The switch in posture has several practical and industry-level implications:

• Regulatory process resumed: Acceptance of the application means the FDA will start its formal assessment of safety and efficacy data, rather than treating the vaccine as not ready for review.
• Market and investor impact: The reversal eases immediate uncertainty for Moderna and vaccine makers who watch FDA signals closely; it also highlights the potential for fast-moving negotiations between regulators and manufacturers when novel vaccine platforms are involved.
• Policy questions remain: Observers note the episode raises broader questions about the FDA’s internal consistency and the speed at which new vaccine technologies can move from company dossiers to public availability.

It’s important to note that agreeing to review a submission is not an approval. The agency will still need to complete its assessment and determine whether the evidence supports authorization or licensure. No new timeline for that decision was provided in the announcements, and final regulatory outcomes will depend on the totality of the clinical and manufacturing data the company submits.